<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01030406</url>
  </required_header>
  <id_info>
    <org_study_id>AP-ADF-114</org_study_id>
    <nct_id>NCT01030406</nct_id>
  </id_info>
  <brief_title>Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acura Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King Pharmaceuticals is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acura Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the relative abuse potential of two
      different doses of orally administered Acurox Tablets to orally administered
      immediate-release (IR) oxycodone HCl tablets in non-dependent recreational opioid users.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the tretament phase, 5 treatments administered were oxycodone HCl/niacin tablets as
      follows: (A) 40/0 mg, (B) 80/0 mg, (C) (40/240 mg, (D) 80/480 mg and (E) 0/0 mg. Each
      treatment was administered as a single dose of 8 tablets once a day at approximately the same
      time each day. All doses were given with water, and all 8 tablets were to be swallowed in 5
      minutes. Doses were separated by 48 (Â± 1) hours. All subjects received each treatment in a
      randomized sequence using a Williams design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Matching white tablets</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Liking at .5 Hours</measure>
    <time_frame>Measure collected at 0.5 hours post-dose</time_frame>
    <description>Drug Liking/Disliking Assessment on a 101 point bipolar visual analog scale (VAS) used to assess response to the question &quot;Do you dislike or like the drug effect you are feeling now?&quot; and anchored in the center with &quot;Neither like nor dislike&quot; (score of 50), on the left with &quot;Dislike an awful lot&quot; (score of 0) and on the right with &quot;Like an awful lot&quot; (score of 100).</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Opioid Abuse</condition>
  <arm_group>
    <arm_group_label>40/0mg taken first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8x oxycodone/niacin 5/0mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80/0mg taken first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8x oxycodone/niacin 10/0mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40/240mg taken first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8x oxycodone/niacin 5/30mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80/480mg taken first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8x oxycodone/niacin 10/60mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0/0mg taken first</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40/0mg taken first</intervention_name>
    <description>8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses</description>
    <arm_group_label>40/0mg taken first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80/0mg taken first</intervention_name>
    <description>8x Oxycodone/Niacin 10/0mg tablets All arms taken with a 48 hour washout between doses</description>
    <arm_group_label>80/0mg taken first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40/240mg taken first</intervention_name>
    <description>8x Oxycodone/Niacin 5/30mg tablets All arms taken with a 48 hour washout between doses</description>
    <arm_group_label>40/240mg taken first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80/480mg taken first</intervention_name>
    <description>8x Oxycodone/Niacin 10/60mg tablets All arms taken with a 48 hour washout between doses</description>
    <arm_group_label>80/480mg taken first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0/0mg taken first</intervention_name>
    <description>Placebo All arms taken with a 48 hour washout between doses</description>
    <arm_group_label>0/0mg taken first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female between 18 and 55 years old.

          -  Subject is in generally good health, including no history of pulmonary disease, and
             has a body mass index (BMI) within 18-33 kg/m2.

          -  Subject is a recreational opioid user (i.e., at least 10 occasions within the past 12
             months, and at least 1 within the past 12 weeks) who is NOT physically dependent on
             opioids (per Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text
             Revision [DSM-IV-TR]); is able to speak, read, and understand English; and will
             provide written informed consent.

          -  Subject has a minimum of a 6th grade reading level as determined by the Investigator
             or by the Rapid Estimation of Adult Literacy in Medicine (REALM).

        Exclusion Criteria:

          -  History or current diagnosis of substance dependence (except nicotine and caffeine)
             and/or alcohol abuse according to the criteria of DSM-IV-TR.

          -  History or current diagnosis of neurological, hepatic, renal, endocrine,
             cardiovascular, gastrointestinal, hematologic, pulmonary, or metabolic disease.

          -  Known allergy or history of hypersensitivity to oxycodone HCl, other opioids, or any
             component of Acurox Tablets.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynne Webster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lifetree Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>December 10, 2009</study_first_submitted>
  <study_first_submitted_qc>December 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2009</study_first_posted>
  <results_first_submitted>June 27, 2018</results_first_submitted>
  <results_first_submitted_qc>October 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2018</results_first_posted>
  <last_update_submitted>October 4, 2018</last_update_submitted>
  <last_update_submitted_qc>October 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abuse Liability</keyword>
  <keyword>Abuse Prevention</keyword>
  <keyword>Abuse Resistance</keyword>
  <keyword>Abuse Deterrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>40/0mg Taken First</title>
          <description>Ocycodone/Naicin 40/0mg Tablets</description>
        </group>
        <group group_id="P2">
          <title>80/0mg Taken First</title>
          <description>Oxycodone/Niacin 80/0mg tablets</description>
        </group>
        <group group_id="P3">
          <title>40/240mg Taken First</title>
          <description>Oxycodone?Niacin 40/240mg tablets</description>
        </group>
        <group group_id="P4">
          <title>80/480mg Taken First</title>
          <description>Oxycodone/Naicin 80/480mg</description>
        </group>
        <group group_id="P5">
          <title>0/0mg Taken First</title>
          <description>Placebo: Tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Crossover design. Subjects took all drugs in randomized order with a 48 hour washout between doses</population>
      <group_list>
        <group group_id="B1">
          <title>40/0mg Taken First</title>
          <description>oxycodone.naicin 40/0mg tablets</description>
        </group>
        <group group_id="B2">
          <title>80/0mg Taken First</title>
          <description>oxycodone.naicin 80/0mg tablets</description>
        </group>
        <group group_id="B3">
          <title>40/240mg Taken First</title>
          <description>oxycodone.naicin 40/240mg tablets</description>
        </group>
        <group group_id="B4">
          <title>80/480mg Taken First</title>
          <description>oxycodone.naicin 80/480mg tablets</description>
        </group>
        <group group_id="B5">
          <title>0/0mg Taken First</title>
          <description>Placebo Tablets</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>2 drop out; 1 protocol violation</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.9" spread="4.83"/>
                    <measurement group_id="B2" value="23.9" spread="4.83"/>
                    <measurement group_id="B3" value="23.9" spread="4.83"/>
                    <measurement group_id="B4" value="23.9" spread="4.83"/>
                    <measurement group_id="B5" value="23.9" spread="4.83"/>
                    <measurement group_id="B6" value="23.9" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug Liking at .5 Hours</title>
        <description>Drug Liking/Disliking Assessment on a 101 point bipolar visual analog scale (VAS) used to assess response to the question &quot;Do you dislike or like the drug effect you are feeling now?&quot; and anchored in the center with &quot;Neither like nor dislike&quot; (score of 50), on the left with &quot;Dislike an awful lot&quot; (score of 0) and on the right with &quot;Like an awful lot&quot; (score of 100).</description>
        <time_frame>Measure collected at 0.5 hours post-dose</time_frame>
        <population>Per protocol completers</population>
        <group_list>
          <group group_id="O1">
            <title>40/0mg</title>
            <description>8x Oxycodone/Naicin 5/0mg tablets</description>
          </group>
          <group group_id="O2">
            <title>80/0mg</title>
            <description>8x Oxycodone/Naicin 10/0mg tablets</description>
          </group>
          <group group_id="O3">
            <title>40/240mg</title>
            <description>8x Oxycodone/Naicin 5/30mg tablets</description>
          </group>
          <group group_id="O4">
            <title>80/480mg</title>
            <description>8x Oxycodone/Naicin 10/60mg tablets</description>
          </group>
          <group group_id="O5">
            <title>0/0mg</title>
            <description>Placebo: Tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Liking at .5 Hours</title>
          <description>Drug Liking/Disliking Assessment on a 101 point bipolar visual analog scale (VAS) used to assess response to the question &quot;Do you dislike or like the drug effect you are feeling now?&quot; and anchored in the center with &quot;Neither like nor dislike&quot; (score of 50), on the left with &quot;Dislike an awful lot&quot; (score of 0) and on the right with &quot;Like an awful lot&quot; (score of 100).</description>
          <population>Per protocol completers</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" spread="16.44"/>
                    <measurement group_id="O2" value="74.7" spread="16.86"/>
                    <measurement group_id="O3" value="47.7" spread="19.96"/>
                    <measurement group_id="O4" value="40.9" spread="22.93"/>
                    <measurement group_id="O5" value="50.3" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>40/0mg</title>
          <description>Oxycodone hcl 40mg</description>
        </group>
        <group group_id="E2">
          <title>80/0mg</title>
          <description>Oxycodone hcl 40mg</description>
        </group>
        <group group_id="E3">
          <title>40/240mg</title>
          <description>Oxycodone hcl 40mg/niacin 240mg</description>
        </group>
        <group group_id="E4">
          <title>80/480ng</title>
          <description>Oxycodone hcl 80mg/niacin 480mg</description>
        </group>
        <group group_id="E5">
          <title>0/0mg</title>
          <description>Placebo: Tablets</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MEDRA (10.0)">nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="49"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="49"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="49"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="49"/>
                <counts group_id="E3" events="36" subjects_affected="36" subjects_at_risk="49"/>
                <counts group_id="E4" events="39" subjects_affected="39" subjects_at_risk="49"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Flushing</sub_title>
                <description>Flushing</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="43" subjects_affected="43" subjects_at_risk="49"/>
                <counts group_id="E4" events="46" subjects_affected="46" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ron Spivey</name_or_title>
      <organization>Acura Pharma</organization>
      <phone>847-705-7709</phone>
      <email>rspivey@acurapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

